Welcome to LookChem.com Sign In|Join Free

CAS

  • or

61317-32-6

Post Buying Request

61317-32-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

61317-32-6 Usage

Description

5-Amino-2(1H)-quinolinone is an organic compound that serves as an intermediate in the synthesis of various pharmaceuticals and chemical compounds. It is characterized by the presence of an amino group attached to the quinoline ring, which contributes to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
5-Amino-2(1H)-quinolinone is used as an intermediate in the synthesis of transient receptor potential vanilloid 1 (TRPV1) antagonists. These antagonists are orally available and have potential applications in treating pain and inflammation, as TRPV1 receptors play a crucial role in the perception of pain and thermal sensations.
In the synthesis process, 5-Amino-2(1H)-quinolinone can be further modified and combined with other chemical entities to create TRPV1 antagonists with improved pharmacological properties, such as increased potency, selectivity, and bioavailability. This makes it a valuable component in the development of novel therapeutic agents for pain management and other related conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 61317-32-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,3,1 and 7 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 61317-32:
(7*6)+(6*1)+(5*3)+(4*1)+(3*7)+(2*3)+(1*2)=96
96 % 10 = 6
So 61317-32-6 is a valid CAS Registry Number.

61317-32-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-amino-1H-quinolin-2-one

1.2 Other means of identification

Product number -
Other names 5-amino-2H-quinolin-2-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:61317-32-6 SDS

61317-32-6Relevant articles and documents

N-(4-acetamidophenyl)-5-acetylfuran-2-carboxamide as a novel orally available diuretic that targets urea transporters with improved PD and PK properties

Wang, Shuyuan,Xu, Yue,Zhao, Yan,Zhang, Shun,Li, Min,Li, Xiaowei,He, Jinzhao,Zhou, Hong,Ge, Zemei,Li, Runtao,Yang, Baoxue

, (2021/10/04)

Urea transporters (UTs) have been identified as new targets for diuretics. Functional deletion of UTs led to urea-selective urinary concentrating defects with relative salt sparing. In our previous study, a UT inhibitor with a diarylamide scaffold, which is denoted as 11a, was demonstrated as the first orally available UT inhibitor. However, the oral bioavailability of 11a was only 4.38%, which obstructed its clinical application. In this work, by replacing the nitro group of 11a with an acetyl group, 25a was obtained. Compared with 11a, 25a showed a 10 times stronger inhibitory effect on UT-B (0.14 μM vs. 1.41 μM in rats, and 0.48 μM vs. 5.82 μM in mice) and a much higher inhibition rate on UT-A1. Moreover, the metabolic stability both in vitro and in vivo and the drug-like properties (permeability and solubility) of 25a were obviously improved compared with those of 11a. Moreover, the bioavailability of 25a was 15.18%, which was 3 times higher than that of 11a, thereby resulting in significant enhancement of the diuretic activities in rats and mice. 25a showed excellent potential for development as a promising clinical diuretic candidate for targeting UTs to treat diseases that require long-term usage of diuretics, such as hyponatremia.

Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells

Kwak, Seung-Hwa,Shin, Seungheon,Lee, Ji-Hyun,Shim, Jin-Kyoung,Kim, Minjeong,Lee, So-Deok,Lee, Aram,Bae, Jinsu,Park, Jin-Hee,Abdelrahman, Aliaa,Müller, Christa E.,Cho, Steve K.,Kang, Seok-Gu,Bae, Myung Ae,Yang, Jung Yoon,Ko, Hyojin,Goddard, William A.,Kim, Yong-Chul

, p. 462 - 481 (2018/04/14)

Screening a compound library of quinolinone derivatives identified compound 11a as a new P2X7 receptor antagonist. To optimize its activity, we assessed structure-activity relationships (SAR) at three different positions, R1, R2 and R3, of the quinolinone scaffold. SAR analysis suggested that a carboxylic acid ethyl ester group at the R1 position, an adamantyl carboxamide group at R2 and a 4-methoxy substitution at the R3 position are the best substituents for the antagonism of P2X7R activity. However, because most of the quinolinone derivatives showed low inhibitory effects in an IL-1β ELISA assay, the core structure was further modified to a quinoline skeleton with chloride or substituted phenyl groups. The optimized antagonists with the quinoline scaffold included 2-chloro-5-adamantyl-quinoline derivative (16c) and 2-(4-hydroxymethylphenyl)-5-adamantyl-quinoline derivative (17k), with IC50 values of 4 and 3 nM, respectively. In contrast to the quinolinone derivatives, the antagonistic effects of the quinoline compounds (16c and 17k) were paralleled by their ability to inhibit the release of the pro-inflammatory cytokine, IL-1β from LPS/IFN-γ/BzATP-stimulated THP-1 cells (IC50 of 7 and 12 nM, respectively). In addition, potent P2X7R antagonists significantly inhibited the sphere size of TS15-88 glioblastoma cells.

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

-

Page/Page column 71, (2010/04/03)

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 61317-32-6